Katie Sharify, a participant in the world’s first human embryonic stem cell trial, describes the accident that qualified her for this groundbreaking study, and her decision to participate.…
Yaron Daniely, PhD, MBA, CEO of Alcobra Pharma talks about MDX, which, if approved, will be the first therapy of its kind for Fragile X Syndrome, the orphan disease…
Kourosh Parsapour, MD, MBA, talks about how to improve patient education, engagement, and compliance through an informative and simple app, PersonalRN (pRN). PersonalRN is a virtual health coach…
Jeremy Lieb, MD, Urologist, Pacific Urology Medical Group, explains that 50% of men with low risk prostate cancer are eligible for active surveillance, yet 9 out of 10…
Paul Roossin, Science Director, Nanotronics Imaging, discusses the goals of the company to use and develop high-tech, cutting-edge microscopes and software to deliver rapid testing and analysis solutions to…
Hair loss, both the more medical forms and more conventional forms, affects many millions of people in the US and across the world. Current treatments include “accidental” drug…
By Will Boggs, MD NEW YORK (Reuters Health) –In mice, treatment with tumor necrosis factor (TNF) or lymphotoxin makes the blood-brain barrier (BBB) selectively permeable at metastasis sites,…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals details the research of Richard A. Young of the Whitehead Institute and his discovery of super-enhancers, large groups of transcriptional enhancers that drive expression…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals elaborates on the breakthrough discovery of super-enhancers, large groups of transcriptional enhancers that drive expression of genes that define cell identity. By identifying…
Why try to develop new drugs and therapies when we can repurpose old ones? Atul J. Butte, MD, PhD, Chief of Division of Systems Medicine at Stanford School…
